In October, the U.S. Food and Drug Administration (FDA) released the

We’ve repeatedly commented on the awkward interface between the cannabinoid industry and the FDA.  The agency is compelled to act given the political noise than cannabis makes, especially CBD in the past couple of years.  The passage of the 2018 Farm Bill increased pressure on the agency to act on CBD regulation, but the agency is accustomed to stakeholders operating within well-defined clinical research parameters.  

In addition to proposed legislation meant to circumvent the agency on CBD regulation, Former leader McConnell’s (R-KY) congress required the agency to update…